Analysis from Phesi shows the impact of COVID-19 on clinical development is continuing to mount, with many clinical trial sites unable to bounce back following suspension in March and April 2020. Phesi’s previous analysis in May 2020 found that, of 300,000 global clinical trial sites, there had been a 38% increase in suspensions from the beginning of the year. Now, new analysis from September 2020 indicates these suspensions peaked in early June, and after an initial drop, have risen again—with over 28,000 sites currently suspended.
Sites did begin recruiting again in June 2020, rising to almost pre-pandemic levels. But the analysis shows that while new sites have appeared, many other investigator sites could go under forever. The sudden increase in recruiting sites is likely due to sponsors scrambling to mitigate the impact of COVID-19 and blindly adding new sites, without analyzing via systematical root cause analysis how well their trials were doing in the first place before the pandemic struck. One important note is that this initial analysis can’t show all the variables, because many sponsors and CROs are yet to release COVID-19 data.
“Even in ‘normal’ times, adding new sites to an ongoing recruiting trial, as is happening here, is a very risky practice without analyzing the true impact of such a move,” commented Dr. Gen Li, President, Phesi. “In many suspended trials, COVID-19 is likely to only have been a superficial trigger for a much deeper problem in the design and enrollment, given around a fifth of trials fail in ordinary circumstances. Adding an extra site can actually just exacerbate existing problems when decisions are not data-led, rather than solving them. Biopharmaceutical organizations planning budgets for 2021 need to take a data-driven view in order to make accurate clinical development decisions that will help them navigate the difficult conditions the sector is facing.”
Phesi’s further analysis of data on clinical trial enrollment closure shows that COVID-19 is also having significant impact on Phase II and III trials.
To read more in the full release, click here.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
FDA Fast Tracks Johnson & Johnson’s Nipocalimab for Fetal Neonatal Alloimmune Thrombocytopenia
March 27th 2024Johnson & Johnson is moving forward with a pair of Phase III trials of nipocalimab to reduce the risk of fetal neonatal alloimmune thrombocytopenia in alloimmunized pregnant patients.